Taken together, these data implicate Fyn in the progression of CML and provide the rationale for our current studies evaluating the correlation between Fyn expression and activity in CML patient specimens. This evidence concerns the gene FYN and chronic myelogenous leukemia, BCR-ABL1 positive.